Clinical Report: EUSOBI Breast Cancer Screening Guidelines and Risk Stratification
Overview
Breast cancer remains the most common cancer among women in Europe, with significant mortality despite advances in diagnosis and treatment. The European Society of Breast Imaging (EUSOBI) emphasizes risk-based screening strategies, highlighting the importance of early detection through mammography to reduce mortality by 20–25%. Risk stratification into average, intermediate, and high categories guides personalized screening recommendations.
Background
Breast cancer affects over 2 million women globally each year, with Europe accounting for over 500,000 new cases annually. Risk factors include age, reproductive history, breast density, genetic mutations, and prior breast conditions. Mammographic breast density notably increases risk by up to sixfold. Screening aims to detect cancers early when they are smaller and less likely to have spread, improving survival outcomes. While breast self-examination is ineffective in reducing mortality, mammography remains the gold standard for early detection.
Data Highlights
Parameter
Value
Annual new breast cancer cases worldwide
>2 million
5-year prevalence worldwide
~8 million
Annual new breast cancer cases in Europe
>500,000
Lifetime risk of breast cancer in European women
~13%
Breast cancer mortality in Europe (2020)
~140,000 deaths
Breast cancer mortality reduction with mammography screening
20–25%
Risk increase with high breast density
2.9–6 fold
Lifetime risk thresholds
Average: <15%, Intermediate: 15–20%, High: >20%
Lifetime risk with BRCA1 mutation
50–85%
Lifetime risk with BRCA2 mutation
45–69%
Key Findings
Breast cancer is the most common cancer in European women, representing about 30% of new female cancer cases.
Risk stratification categories: average (<15%), intermediate (15–20%), and high (>20%) lifetime risk guide screening protocols.
Mammographic breast density significantly increases breast cancer risk and is incorporated into risk prediction models.
Genetic mutations such as BRCA1 and BRCA2 confer very high lifetime risks (up to 85%).
Mammography screening reduces breast cancer mortality by approximately 20–25% through early detection and downstaging.
Emerging risk assessment tools include deep learning applied to mammographic images to improve individualized risk prediction.
Clinical Implications
Clinicians should incorporate individual risk factors including genetic predisposition and breast density when recommending breast cancer screening schedules. Mammography remains the cornerstone of screening for average and intermediate risk women, while high-risk women may require earlier and more intensive surveillance. Personalized risk assessment models and ongoing trials may soon refine screening strategies further to optimize early detection and reduce mortality.
Conclusion
EUSOBI guidelines emphasize a risk-adapted approach to breast cancer screening, leveraging mammography and advanced risk prediction to improve early detection. This strategy aims to reduce mortality by identifying cancers at a more treatable stage, particularly in high-risk populations.
